U.S. Markets closed
  • S&P 500

    4,163.29
    -10.56 (-0.25%)
     
  • Dow 30

    34,327.79
    -54.34 (-0.16%)
     
  • Nasdaq

    13,379.05
    -50.93 (-0.38%)
     
  • Russell 2000

    2,227.12
    +2.49 (+0.11%)
     
  • Crude Oil

    66.38
    +1.01 (+1.55%)
     
  • Gold

    1,867.30
    +29.20 (+1.59%)
     
  • Silver

    28.32
    +0.95 (+3.47%)
     
  • EUR/USD

    1.2155
    +0.0009 (+0.0729%)
     
  • 10-Yr Bond

    1.6400
    +0.0050 (+0.31%)
     
  • Vix

    19.72
    +0.91 (+4.84%)
     
  • GBP/USD

    1.4139
    +0.0037 (+0.2630%)
     
  • USD/JPY

    109.2370
    -0.1100 (-0.1006%)
     
  • BTC-USD

    44,737.32
    +367.59 (+0.83%)
     
  • CMC Crypto 200

    1,243.36
    +45.44 (+3.79%)
     
  • FTSE 100

    7,032.85
    -10.76 (-0.15%)
     
  • Nikkei 225

    27,824.83
    -259.64 (-0.92%)
     

Europe Approved Biogen’s Elocta, Topped XBI’s Large-Cap Stocks

Peter Neil

Mid-Cap and Small-Cap Biotech Stocks Rose, Pushed XBI Up

(Continued from Prior Part)

XBI large-cap stocks remain muted

The SPDR S&P Biotech ETF’s (XBI) large-cap stocks remained low. They gave returns of 0.3% on November 25, 2015. XBI’s large-cap stocks underperformed XBI but outperformed the SPDR S&P 500 ETF (SPY). Out of the 13 large-cap stocks that XBI holds, six stocks ended in red and seven stocks gave positive returns. The large-cap stocks account for ~13% of XBI’s portfolio. XBI’s large-cap stocks include stocks like Incyte (INCY), Biomarin Pharmaceuticals (BMRN), and Alkermes (ALKS). They had returns of 3.3%, -1.8%, and -0.25% respectively.

The above graph shows the performance of XBI’s large-cap stocks in relation to XBI and SPY. Since the beginning of November 2015, XBI’s large-cap stocks underperformed XBI and SPY. XBI’s large-cap stocks returned -0.2%, XBI returned 8.8%, and SPY returned 0.7%.

Europe approved Biogen’s Elocta

Biogen (BIIB) rose 1% on November 25, 2015. According to the press release, Biogen and Swedish Orphan Biovitrum AB (SOBI) announced that “the European Commission (EC) has approved ELOCTA® (rFVIIIFc) for the treatment of haemophilia A in all 28 European Union member states, as well as Iceland, Liechtenstein and Norway. ELOCTA, a recombinant factor VIII Fc fusion protein with an extended half-life, will be the first haemophilia A treatment in the EU to offer prolonged protection against bleeding episodes with prophylactic injections every three to five days.”

Biogen closed at $292.30. It was trading 5.7% below the 100-day moving average price of $309.85. However, the stock passed the 20-day moving average price of $292.19. Biogen’s trailing 12-month PE (price-to-earnings) ratio stood at 19.09x. Biogen’s book value is $47.43 per share. With its current price, the stock is trading at a PBV (price-to-book value) ratio of 6.16x compared to the funds industry average of 13.16x. Biogen has a weight of 1% in XBI’s portfolio.

Continue to Next Part

Browse this series on Market Realist: